HOME Research Insight The Key Growth Strategies Adopted by the Top Companies (profiled in the report) include Partnerships, Collaborations, and Agreements; Product Launches and Approvals; Expansion; and Acquisitions. in the Injectable Drug Delivery Market



The Key Growth Strategies Adopted by the Top Companies (profiled in the report) include Partnerships, Collaborations, and Agreements; Product Launches and Approvals; Expansion; and Acquisitions. in the Injectable Drug Delivery Market


The leading players in the market are Becton, Dickinson and Company (U.S.), Baxter International (U.S.), Pfizer (U.S.), Gerresheimer AG (Germany), Schott AG (Germany), Eli Lilly and Company (U.S.), and Terumo Corporation (Japan).

Companies are focused on organic strategies such as product launches. This strategy helped the market players to build a strong position in the market, which helped in increasing demand of customers and to expand their presence in the global market.

This research study involves the use of extensive secondary sources; directories; and databases such as Hoovers, Bloomberg Business, Factiva, and Avention; white papers; annual reports; company house documents; and SEC filings of companies.

For estimating the size of the injectable drug delivery market, the segmental market revenues were obtained from secondary sources through extensive primary interviews. The segment-level markets were then added up to reach the total market size of each segment (Type, Formulation Packaging, Therapeutic Application, Usage Pattern, Site of Administration, Distribution Channel, Facility of Use, and Regions). The injectable drug delivery market size was derived by adding the markets of all these segments. The total market derived through the bottom-up approach was again validated through secondary sources and interviews.

The overall market size derived by the bottom-up approach was used in the top-down procedure to estimate the size of the injectable drug delivery through the percentage splits obtained from secondary and primary research for each product segment

The overall growth strategies adopted from 2013 to 2016 includes acquisition, agreements, collaboration, contracts, expansions, product launches, and partnerships. Companies adopted product launches and approvals to strengthen their customer base. Major players, namely, Becton, Dickinson and Company (U.S.), Baxter International (U.S.), Pfizer (U.S.), Gerresheimer AG (Germany), Schott AG (Germany), Eli Lilly and Company (U.S.), and Terumo Corporation (Japan) adopted product launches and approvals to expand their customer base and strengthen their position in the market.

In November 2016, Becton, Dickinson and Company collaborated with Eli Lilly & Company (U.S.) to launch the FDA-approved BD U-500 Insulin Syringe. This is used by patients using Humulin R U-500 insulin for the treatment of diabetes. This has helped the company enhance its product portfolio for the treatment of diabetes. Further, in January 2016, SCHOTT added new closure systems (rigid caps) to its existing wide portfolio of prefillable syringes (PFS), which offers an easy-to-use twist-off mechanism. This helped the company offer advanced products and strengthen its customer base.

Related Reports:

Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Cancer), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), Distribution Channel (Hospital), Patient Care Setting (Hospital, Home Care) - Forecast to 2021

Contact:
Mr.Rohan
MarketsandMarkets™
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
1-888-600-6441
Email: sales@marketsandmarkets.com

 

 

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports